Oakland, CA, United States of America

Alexandre Charles Michel Iannello

USPTO Granted Patents = 5 

Average Co-Inventor Count = 4.2

ph-index = 1

Forward Citations = 3(Granted Patents)


Company Filing History:


Years Active: 2023-2025

Loading Chart...
5 patents (USPTO):Explore Patents

Title: Innovations of Alexandre Charles Michel Iannello

Introduction

Alexandre Charles Michel Iannello is a notable inventor based in Oakland, CA. He has made significant contributions to the field of immunology, particularly through his innovative work on engineered immunostimulatory bacterial strains. With a total of five patents to his name, Iannello's research focuses on enhancing anti-tumor activity through the modification of bacterial strains.

Latest Patents

Iannello's latest patents include the development of engineered immunostimulatory bacterial strains that have enhanced colonization of tumors and the tumor microenvironment. These bacteria are modified to improve their effectiveness in targeting tumor-resident immune cells and enhancing anti-tumor activity. The modifications involve the deletion of genes encoding flagella and the alteration of pagP to produce inactive products. Additionally, these bacteria may have genomic modifications that make them auxotrophs for adenosine or purine. The methods developed by Iannello aim to inhibit the growth or reduce the volume of solid tumors through the administration of these immunostimulatory bacteria.

Career Highlights

Iannello is currently associated with Actym Therapeutics, Inc., where he continues to advance his research in immunotherapy. His work has the potential to revolutionize cancer treatment by utilizing engineered bacteria to stimulate the immune response against tumors.

Collaborations

Some of Iannello's notable coworkers include Christopher D Thanos and Laura Hix Glickman, who contribute to the collaborative efforts in his research endeavors.

Conclusion

Alexandre Charles Michel Iannello's innovative work in the field of immunology showcases the potential of engineered bacterial strains in cancer therapy. His contributions are paving the way for new treatment methodologies that could significantly impact patient outcomes.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…